Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Generally healthy, postmenopausal women who seek treatment for hot flushes
Minimum of 7 moderate to severe hot flushes per day or 50 per week recorded for 7 consecutive days during screening
Body Mass Index (BMI) less than or equal to 40 kg/m2
Other inclusions apply.
Hypersensitivity to Venlafaxine
History of seizure disorder
History of myocardial infarction or unstable angina within 6 months